Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Evaxion A/S changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 12 | 12 | 0 |
| Shares | 1.08M | 678.5K | −399.3K (−37.0%) |
| Value | $4.76M | $2.06M | −$2.70M (−56.7%) |
New holders (3)
Institutions that held Evaxion A/S at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 12,750 | $39.0K | 0.00% |
| Citigroup Inc | 3,195 | $10.0K | 0.00% |
| Captrust Financial Advisors | 339 | $1.00K | 0.00% |
Sold out (3)
Institutions that held Evaxion A/S at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Renaissance Technologies LLC | 20,270 | $90.0K |
| Susquehanna International Group, LLP | 15,090 | $67.0K |
| Tower Research Capital LLC (TRC) | 427 | $2.00K |